|
Market Cap (24-Jun) $6,789,696 (1,468th) |
Close (30-Jun) $0.042 |
Volume (30-Jun) 582,113 |
Shortsold (6-Dec) 611,822 (0.21%) (374th) |
|
52w High $0.021 |
52w Low $0.009 |
P/E 11.60 |
EPS -0.01 |
ACR released this announcement to the ASX on 15 September 2021, 9:04. The announcement is not marked as price sensitive, and is 6 page(s) in length and 24.25kb in size.
You can view all announcements from ACR and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACR was 0.004% short sold according to ASIC data. It was ranked the 605th most shorted stock on the ASX. It is now ranked as the 374th most shorted stock on the ASX with 0.210% of total shares short sold as of the latest reported data (06 December 2024).
| Other Recent Announcements from ACR | |
|---|---|
| Appendix 3Y Brooke | 16 June 2023, 9:27 |
| Application for quotation of securities - ACR | 16 June 2023, 9:25 |
| 4th FDA ANDA approval received - Dapsone Gel, 5% | 7 June 2023, 10:35 |
| Application for quotation of securities - ACR | 15 September 2021, 9:04 |
| Acrux's fifth generic dossier accepted by FDA for review | 13 September 2021, 8:22 |
| Acrux Investor Presentation - September 2021 | 2 September 2021, 8:29 |
| US Launch - Testosterone Topical Solution | 26 August 2021, 9:34 |
You must be logged in to post a reply.
